scholarly journals Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation

2004 ◽  
Vol 34 (10) ◽  
pp. 2824-2833 ◽  
Author(s):  
Arvind Chhabra ◽  
Shikhar Mehrotra ◽  
Nitya G. Chakraborty ◽  
Bijay Mukherji ◽  
David I. Dorsky
Keyword(s):  
Dendritic Cells ◽  
Tumor Antigen ◽  
Protein Translocation ◽  
Human Tumor ◽  
Cross Presentation

scholarly journals Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells

2001 ◽  
Vol 167 (3) ◽  
pp. 1795-1802 ◽  
Author(s):  
Iris Motta ◽  
Fabrice André ◽  
Annick Lim ◽  
James Tartaglia ◽  
William I. Cox ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Tumor Antigen ◽  
Cross Presentation ◽  
Canarypox Virus

scholarly journals Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response

2000 ◽  
Vol 97 (5) ◽  
pp. 2185-2190 ◽  
Author(s):  
V. Russo ◽  
S. Tanzarella ◽  
P. Dalerba ◽  
D. Rigatti ◽  
P. Rovere ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Tumor Antigen ◽  
Cell Response ◽  
Human Tumor ◽  
T Cell Response ◽  
Class I ◽  
Apoptotic Cells

scholarly journals Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells

2013 ◽  
Vol 19 (5) ◽  
pp. 1147-1158 ◽  
Author(s):  
Jean-Baptiste Guillerme ◽  
Nicolas Boisgerault ◽  
David Roulois ◽  
Jérémie Ménager ◽  
Chantal Combredet ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Tumor Cells ◽  
Virus Vaccine ◽  
Tumor Antigen ◽  
Measles Virus ◽  
Plasmacytoid Dendritic Cells ◽  
Cross Presentation ◽  
Infected Tumor

scholarly journals Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity

2005 ◽  
Vol 175 (3) ◽  
pp. 1628-1635 ◽  
Author(s):  
Casey A. Carlos ◽  
Hui Fang Dong ◽  
O. M. Zack Howard ◽  
Joost J. Oppenheim ◽  
Franz-Georg Hanisch ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Tumor Antigen ◽  
Human Tumor ◽  
Immature Dendritic Cells

scholarly journals Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells

2020 ◽  
Vol 8 (1) ◽  
pp. e000474 ◽  
Author(s):  
Yifan Zhou ◽  
Natalie Slone ◽  
Taylor T Chrisikos ◽  
Oleksandr Kyrysyuk ◽  
Rachel L Babcock ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Tumor Antigen ◽  
Checkpoint Blockade ◽  
Antitumor Efficacy ◽  
Poly I:C ◽  
Tumor Control ◽  
Cross Presentation ◽  
Presentation Activity

BackgroundType 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103+cDC1s in mice, CD141+cDC1s in humans) are linked with improved tumor control, yet the efficacy of immunotherapy using this population is understudied.MethodsWe generated murine CD103+cDC1s in vitro and examined their expression of cDC1-related factors, antigen cross-presentation activity, and accumulation in tumor-draining lymph nodes (TdLNs). The antitumor efficacy of the in vitro-generated CD103+cDC1s was studied in murine melanoma and osteosarcoma models. We evaluated tumor responses on vaccination with CD103+cDC1s, compared these to vaccination with monocyte-derived DCs (MoDCs), tested CD103+cDC1 vaccination with checkpoint blockade, and examined the antimetastatic activity of CD103+cDC1s.ResultsIn vitro-generated CD103+cDC1s produced cDC1-associated factors such as interleukin-12p70 and CXCL10, and demonstrated antigen cross-presentation activity on stimulation with the toll-like receptor 3 agonist polyinosinic:polycytidylic acid (poly I:C). In vitro-generated CD103+cDC1s also migrated to TdLNs following poly I:C treatment and intratumoral delivery. Vaccination with poly I:C-activated and tumor antigen-loaded CD103+cDC1s enhanced tumor infiltration of tumor antigen-specific and interferon-γ+CD8+T cells, and suppressed melanoma and osteosarcoma growth. CD103+cDC1s showed superior antitumor efficacy compared with MoDC vaccination, and led to complete regression of 100% of osteosarcoma tumors in combination with CTLA-4 antibody-mediated checkpoint blockade. In vitro-generated CD103+cDC1s effectively protected mice from pulmonary melanoma and osteosarcoma metastases.ConclusionsOur data indicate an in vitro-generated CD103+cDC1 vaccine elicits systemic and long-lasting tumor-specific T cell-mediated cytotoxicity, which restrains primary and metastatic tumor growth. The CD103+cDC1 vaccine was superior to MoDCs and enhanced response to immune checkpoint blockade. These results indicate the potential for new immunotherapies based on use of cDC1s alone or in combination with checkpoint blockade.

Sign in / Sign up

Export Citation Format

Share Document